CN Patent

CN104039325A — 布鲁顿酪氨酸激酶(btk)抑制剂的用途

Assigned to Pharmacyclics LLC · Expires 2014-09-10 · 12y expired

What this patent protects

本发明提供了用于治疗血液癌症的方法，其包括向被鉴定为在施用不可逆Btk抑制剂后具有增加的来自恶性肿瘤的淋巴细胞亚群动员的受试者施用抗癌剂。还提供了鉴定用于治疗的受试者和分析在施用不可逆Btk抑制剂后从血液恶性肿瘤动员的细胞的方法。

USPTO Abstract

本发明提供了用于治疗血液癌症的方法，其包括向被鉴定为在施用不可逆Btk抑制剂后具有增加的来自恶性肿瘤的淋巴细胞亚群动员的受试者施用抗癌剂。还提供了鉴定用于治疗的受试者和分析在施用不可逆Btk抑制剂后从血液恶性肿瘤动员的细胞的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN104039325A
Jurisdiction
CN
Classification
—
Expires
2014-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.